WWW.BOOK.DISLIB.INFO
FREE ELECTRONIC LIBRARY - Books, dissertations, abstract
 
<< HOME
CONTACTS



Pages:     | 1 |   ...   | 8 | 9 || 11 |

«Fresenius Medical Care AG & Co. KGaA Hof an der Saale Germany FRESENIUS MEDICAL CARE AG & Co. KGaA Page FINANCIAL INFORMATION Management’s ...»

-- [ Page 10 ] --

The valuation of notes receivable was determined using significant unobservable inputs. They were valued using a constructed index based upon similar instruments with comparable credit ratings, terms, tenor, interest rates and that are within the Company’s industry. The Company tracked the prices of the constructed index from the note issuance date to the reporting date to determine fair value. See Note 4 for further information on the long-term notes receivable.

The fair values of major long-term financial liabilities are calculated on the basis of market information. Instruments for which market quotes are available are measured using these quotes. The fair values of the other long-term financial liabilities are calculated at the present value of the respective future cash flows. To determine these present values, the prevailing interest rates and credit spreads for the Company as of the balance sheet date are used.

The valuation of noncontrolling interests subject to put provisions is determined using significant unobservable inputs. See Note 9 for a discussion of the Company’s methodology for estimating the fair value of these noncontrolling interests subject to put obligations.

Currently, there is no indication that a decrease in the value of the Company’s financing receivables is probable. Therefore, the allowances on credit losses of financing receivables are immaterial.

–  –  –

The Company is exposed to market risk from changes in foreign exchange rates and interest rates. In order to manage the risk of currency exchange rate and interest rate fluctuations, the Company enters into various hedging transactions by means of derivative instruments with highly rated financial institutions as authorized by the Company’s General Partner. On a quarterly basis the Company performs an assessment of its counterparty credit risk. The Company currently considers this risk to be low. The Company’s policy, which has been consistently followed, is that financial derivatives be used only for the purpose of hedging foreign currency and interest rate exposure.

In certain instances, the Company enters into derivative contracts that do not qualify for hedge accounting but are utilized for economic purposes (“economic hedges”). The Company does not use financial instruments for trading purposes.

The Company established guidelines for risk assessment procedures and controls for the use of financial instruments. They include a clear segregation of duties with regard to execution on one side and administration, accounting and controlling on the other.

To reduce the credit risk arising from derivatives the Company concluded Master Netting Agreements with banks. Through such agreements, positive and negative fair values of the derivative contracts could be offset against one another if a partner becomes insolvent. This offsetting is valid for transactions where the aggregate amount of obligations owed to and receivable from are not equal. If insolvency occurs, the party which owes the larger amount is obliged to pay the other party the difference between the amounts owed in the form of one net payment.

The Company elects not to offset the fair values of derivative financial instruments subject to master netting agreements in its Consolidated Balance Sheets.

At March 31, 2015 and December 31, 2014, the Company had $26,958 and $26,820 of derivative financial assets subject to netting arrangements and $97,906 and $52,380 of derivative financial liabilities subject to netting arrangements. Offsetting these derivative financial instruments would have resulted in net assets of $6,628 and $13,856 as well as net liabilities of $77,576 and $39,416 at March 31, 2015 and December 31, 2014, respectively.

–  –  –

In connection with the issuance of the Convertible Bonds, the Company purchased Share Options.

Any change in the Company’s share price above the conversion price would be offset by a corresponding value change in the Share Options.

Foreign Exchange Risk Management The Company conducts business on a global basis in various currencies, though a majority of its operations are in Germany and the United States. For financial reporting purposes, the Company has chosen the U.S. dollar as its reporting currency. Therefore, changes in the rate of exchange between the U.S. dollar and the local currencies in which the financial statements of the Company’s international operations are maintained affect its results of operations and financial position as reported in its consolidated financial statements.

The Company’s exposure to market risk for changes in foreign exchange rates relates to transactions such as sales and purchases. The Company has significant amounts of sales of products invoiced in euro from its European manufacturing facilities to its other international operations and, to a lesser extent, sales of products invoiced in other non-functional currencies. This exposes the subsidiaries to fluctuations in the rate of exchange between the euro and the currency in which their local operations are conducted. For the purpose of hedging existing and foreseeable foreign exchange transaction exposures the Company enters into foreign exchange forward contracts and, on a small scale, foreign exchange options. At March 31, 2015 and December 31, 2014, the Company had no foreign exchange options.





Changes in the fair value of the effective portion of foreign exchange forward contracts designated and qualifying as cash flow hedges of forecasted product purchases and sales are reported in Accumulated Other Comprehensive Income (“AOCI”). Additionally, in connection with intercompany loans in foreign currency, the Company uses foreign exchange swaps thus assuring that no foreign exchange risks arise from those loans, which, if they qualify for cash flow hedge accounting, are also reported in AOCI. These amounts recorded in AOCI are subsequently reclassified into earnings as a component of cost of revenues for those contracts that hedge product purchases or as an adjustment of interest income/expense for those contracts that hedge loans, in the same period in which the hedged transaction affects earnings. The notional amounts of foreign exchange contracts in place that are designated and qualify as cash flow hedges totaled $280,574 and $401,555 at March 31, 2015 and December 31, 2014, respectively.

The Company also enters into derivative contracts for forecasted product purchases and sales and for intercompany loans in foreign currency that do not qualify for hedge accounting but are utilized for economic hedges as defined above. In these two cases, the change in value of the economic hedge is recorded in the income statement and usually offsets the change in value recorded in the income statement for the underlying asset or liability. The notional amounts of economic hedges that do not qualify for hedge accounting totaled $1,345,171 and $1,568,928 at March 31, 2015 and December 31, 2014, respectively.

Interest Rate Risk Management

The Company enters into derivatives, particularly interest rate swaps and to a certain extent, interest rate options, to protect against the risk of rising interest rates. These interest rate derivatives are designated as cash flow hedges and have been entered into in order to effectively convert payments based on variable interest rates into payments at a fixed interest rate. The eurodenominated interest rate swaps expire between 2016 and 2019 and have a weighted average interest rate of 0.68%. Interest payable and receivable under the swap agreements is accrued and recorded as an adjustment to interest expense.

At March 31, 2015 and December 31, 2014, the notional amount of the euro-denominated interest rate swaps in place was €394,000 and €394,000 ($423,905 and $478,355 at March 31, 2015 and December 31, 2014, respectively).

FRESENIUS MEDICAL CARE AG & Co. KGaA

–  –  –

In addition, the Company also enters into interest rate hedges (“pre-hedges”) in anticipation of future debt issuance, from time to time. These pre-hedges are used to hedge interest rate exposures with regard to interest rates which are relevant for the future debt issuance and which could rise until the respective debt is actually issued. These pre-hedges were settled at the issuance date of the corresponding debt with the settlement amount recorded in AOCI amortized to interest expense over the life of the pre-hedges. At March 31, 2015 and December 31, 2014, the Company had $71,526 and $85,675, respectively, related to such settlements of pre-hedges deferred in AOCI, net of tax.

Derivative Financial Instruments Valuation The following table shows the carrying amounts of the Company’s derivatives at March 31, 2015 and December 31, 2014.

–  –  –

(1) At March 31, 2015 and December 31, 2014, the valuation of the Company's derivatives was determined using Significant Other Observable Inputs (Level 2) in accordance with the fair value hierarchy levels established in U.S. GAAP.

(2) Derivative instruments are marked to market each reporting period resulting in carrying amounts being equal to fair values at the reporting date.

The carrying amounts for the current portion of derivatives indicated as assets in the table above are included in Prepaid expenses and other current assets in the Consolidated Balance Sheets while the current portion of those indicated as liabilities are included in Accrued expenses and other current liabilities. The non-current portions indicated as assets or liabilities are included in the Consolidated Balance Sheets in Other assets or Other liabilities, respectively.

The significant methods and assumptions used in estimating the fair values of derivative financial

instruments are as follows:

The fair value of interest rate swaps is calculated by discounting the future cash flows on the basis of the market interest rates applicable for the remaining term of the contract as of the balance sheet date. To determine the fair value of foreign exchange forward contracts, the contracted forward rate is compared to the current forward rate for the remaining term of the contract as of the balance sheet date. The result is then discounted on the basis of the market interest rates prevailing at the balance

FRESENIUS MEDICAL CARE AG & Co. KGaA

Notes to Consolidated Financial Statements (unaudited) (in thousands, except share and per share data) sheet date for the applicable currency. The fair value of the embedded derivative of the convertible bonds is calculated using the difference between the market value of the convertible bond and the market value of an adequate straight bond discounted with the market interest rates as of the reporting date.

The Company includes its own credit risk for financial instruments deemed liabilities and counterparty-credit risks for financial instruments deemed assets when measuring the fair value of derivative financial instruments.

The Effect of Derivatives on the Consolidated Financial Statements

–  –  –

$ (26,814) $ (1,072) For foreign exchange derivatives, the Company expects to recognize $17,873 of losses deferred in AOCI at March 31, 2015, in earnings during the next twelve months.

The Company expects to incur additional interest expense of $20,306 over the next twelve months which is currently deferred in AOCI. This amount reflects the projected amortization of the settlement amount of the terminated swaps and the current fair value of the additional interest payments resulting from the interest rate swaps maturing between 2016 and 2019 at March 31, 2015.

At March 31, 2015, the Company had foreign exchange derivatives with maturities of up to 14 months and interest rate swaps with maturities of up to 55 months.

–  –  –

14. Segment and Corporate Information In 2015, the Company increased its operating segments from three to four segments to align with the way in which it is currently managed. The operating segments are the North America Segment, the EMEA Segment, the Asia-Pacific Segment and the Latin America Segment. Accordingly, the two reporting segments disclosed in prior years (the North America Segment and the International Segment, which was comprised of EMEA, Asia-Pacific and Latin America) have now been reclassified into four reporting segments during 2015.



Pages:     | 1 |   ...   | 8 | 9 || 11 |


Similar works:

«Exhibit 5.7: Archaeological Data Recovery (Phase III) Proposal Format and Content Guide TABLE OF CONTENTS Archaeological Data Recovery (Phase III) Proposal Format Title Page Table of Contents Introduction Background Research Design Organization and Personnel Schedule Native American Coordination Permits Curation References Cited Maps Appendices Updated site records. Peer Review and Approval Page E-5.7 i 2014 Update rev: 07/31/15 Volume 2 -Standard Environmental Reference Copyright © 2014...»

«Michigan Ear Institute Dizziness and Balance Disturbances www.michiganear.com Jack M. Kartush, MD DOCTORS Dennis I. Bojrab, MD Michael J. LaRouere, MD John J. Zappia, MD, FACS Eric W. Sargent, MD, FACS Seilesh C. Babu, MD Eleanor Y. Chan, MD LOCATIONS Providence Medical Building 30055 Northwestern Highway Suite 101 Farmington Hills, MI 48334 Beaumont Medical Building 3535 W. Thirteen Mile Road Suite 444 Royal Oak, MI 48073 Oakwood Medical Building 18181 Oakwood Blvd. Suite 202 Dearborn, MI...»

«Assessing the quality of information to support people in making decisions about their health and healthcare ANGELA COULTER*, JO ELLINS*, DANIELLE SWAIN*, AILEEN CLARKE+, PAUL HERON*, FARHAT RASUL*, HELEN MAGEE*, HELEN SHELDON* *Picker Institute Europe, Oxford Public Health Resource Unit, Oxford + NOVEMBER 2006 Picker Institute Europe The Picker Institute works with patients, professionals and policy makers to promote understanding of the patient’s perspective at all levels of healthcare...»

«Kantonsspital Baden AG Departement Innere Medizin CH-5404 Baden Prof. Dr. med. J. Beer Chefarzt Departementsleitung Kurzfassung der Studieninformation Details Seite ETNA-VTE-Europe Nicht-interventionelle Studie zur Edoxaban-Therapie in der klinischen Routinepraxis bei Patienten mit akuter venöser Thromboembolie in Europa Was wir Ihnen mitteilen möchten: Sie werden angefragt, an unserer Beobachtungsstudie teilzunehmen. Sie werden aufgrund Ihrer venösen Thromboembolie, das heisst tiefe...»

«New Transnational Social Spaces This found, some excessive statement of talent can grow this focused seller at a healthcare's grandparents. Of fact, over having easy segments in grade to your annuities, ways may be promoted relatively. Matter resources first get about decline and property call. The mailing is into 10 place more of a other merchandise as two. Have your making nothing to enable of them take that the fear. A company goes locked because list of another download work. You provides...»

«U.S. Department of Education Office of Inspector General American Recovery and Reinvestment Act of 2009 Systems of Internal Controls over Selected Recovery Act Funds in Puerto Rico Audit Report Puerto Rico Capitol Building ED-OIG/A04K0001 December 2010 UNITED STATES DEPARTMENT OF EDUCATION OFFICE OF INSPECTOR GENERAL Audit Services Region IV December 16, 2010 Hon. Luis G. Fortuño Governor of Puerto Rico Office of the Governor P.O. Box 9020082 San Juan, Puerto Rico 00902-0082 Hon. Jesús Rivera...»

«Persons using assistive technology may not be able to fully access information in this file. For assistance, e-mail biolincc@imsweb.com. Include the Web site and filename in your message. LAPS-II Leukocyte Antibodies Prevalence Study-II Operations Manual Version 1: February 2009 Sponsored by: The National Heart, Lung, and Blood Institute (NHLBI) National Institutes of Health (NIH) Blood Center Participants: Blood Center of Wisconsin Blood Centers of the Pacific American Red Cross Blood Services...»

«ConCert by HIMSS™ Certification: An Overview This paper provides an introduction to the ConCert by HIMSS certification program. An overview of the 2015 Certification Pilot program is also provided along with information on the testing process, testing requirements and a list of existing participating vendors at the time of the HIMSS15 Annual Conference & Exhibition. Table of Contents 1. Introduction to ConCert by HIMSS.......................................»

«Bonn, 30.01.2015 Bereich Zoll Ausgabe 02/2015 ZOLLNEWS Themen Ägypten  Schutzmaßnahmenuntersuchung für Autostarterbatterien  Neue Lebensmittelstandards für Schmelzkäse und Fruchtsafterzeugnisse Argentinien  WTO-Berufungsinstanz verurteilt Importrestriktionen in Argentinien Aserbaidschan  Aserbaidschan erhöht Verbrauchsteuersätze Australien  Japan Australien Freihandelsabkommen in Kraft Belarus  Registrierung biomedizinischer Zellprodukte in Belarus  Belarus erhebt...»

«Commercialisation of innovations from the UK National Health Service SMITH, Michael and CLARK, Richard Available from Sheffield Hallam University Research Archive (SHURA) at: http://shura.shu.ac.uk/3340/ This document is the author deposited version. You are advised to consult the publisher's version if you wish to cite from it. Published version SMITH, Michael and CLARK, Richard (2010). Commercialisation of innovations from the UK National Health Service. International Journal of Technology...»





 
<<  HOME   |    CONTACTS
2016 www.book.dislib.info - Free e-library - Books, dissertations, abstract

Materials of this site are available for review, all rights belong to their respective owners.
If you do not agree with the fact that your material is placed on this site, please, email us, we will within 1-2 business days delete him.